Archive

Skip to content The CRC Digest Phase II trial tests pembrolizumab plus chemotherapy in MSS colorectal cancer — Clinical Colorectal Cancer A phase II study evaluated pembrolizumab combined with capecitabine and bevacizumab in patients with microsatellite stable/mismatch repair-proficient metastatic colorectal cancer. This trial addresses the challenge that most colorectal cancers

Skip to content The CRC Digest ▪ SCREENING Blood-based DNA tests show promise for colorectal cancer screening — Critical Reviews in Oncology/Hematology A systematic review and meta-analysis evaluated the diagnostic accuracy of blood-based circulating tumor DNA (ctDNA) tests for detecting advanced colorectal neoplasia in asymptomatic, average-risk populations. The analysis examined how

Skip to content The CRC Digest ▸ TREATMENT Real-world data compares late-line treatment options for metastatic colorectal cancer — ESMO Open A multicenter study compared outcomes of trifluridine/tipiracil (FTD-TPI) plus bevacizumab versus FTD-TPI alone or regorafenib in patients with pretreated metastatic colorectal cancer. The analysis included real-world data on effectiveness and

Skip to content The CRC Digest ◆ TRIAL DATA Chemotherapy alone may be as effective as chemoradiation before rectal cancer surgery — Journal of Clinical Oncology The CONVERT trial compared neoadjuvant chemotherapy with CAPOX (capecitabine and oxaliplatin) versus chemoradiation for locally advanced rectal cancer with uninvolved mesorectal fascia. This phase III trial

Skip to content The CRC Digest ◆ TRIAL DATA Long-term results show benefit of chemotherapy after liver metastasis surgery — Journal of Clinical Oncology The JCOG0603 trial compared hepatectomy (liver surgery) followed by mFOLFOX6 chemotherapy versus hepatectomy alone for patients with liver metastases from colorectal cancer. This phase II/III randomized trial

Skip to content The CRC Digest ◆ TRIAL DATA Adding immunotherapy to intensive chemotherapy shows promise in hard-to-treat colorectal cancer — Nature Communications The phase II NIVACOR trial tested nivolumab (an immunotherapy drug) combined with FOLFOXIRI/bevacizumab chemotherapy as first-line treatment in patients with RAS or BRAF-mutated metastatic colorectal cancer. These mutations